PUBLICATIONS Archives - Page 5 of 8

Oncology

12/2016

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium

Graviton

Love6

Oncology

12/2016

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

EBioMedicine

natalia

Love6

NASH

11/2016

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

AASLD The Liver Meeting

Graviton

Love6

Oncology

11/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

NCRI Cancer Conference

Graviton

Love4

Oncology

09/2016

Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

Precison: Lung Cancer R&D Summit

natalia

Love6

Oncology

08/2016

DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

Journal of Cell Signaling

natalia

Love6

Oncology

06/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting

Graviton

Love4

Oncology

04/2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

AACR Annual Meeting

Graviton

Love4

Oncology

04/2016

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

AACR Annual Meeting

Graviton

Love4

Oncology

03/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

International Congress on Targeted Anticancer Therapies

Graviton

Love4

PUBLICATIONS

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

Site Map

Contact Us

Virtual Investor and Analyst Day